Royce & Associates LP Has $8.18 Million Position in Integer Holdings Co. (NYSE:ITGR)

Royce & Associates LP lifted its holdings in shares of Integer Holdings Co. (NYSE:ITGR) by 31.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 61,759 shares of the medical equipment provider’s stock after buying an additional 14,919 shares during the period. Royce & Associates LP’s holdings in Integer were worth $8,184,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Huntington National Bank boosted its position in Integer by 8,933.3% during the third quarter. Huntington National Bank now owns 271 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 268 shares during the last quarter. Natixis Advisors LLC grew its stake in shares of Integer by 3.7% in the third quarter. Natixis Advisors LLC now owns 45,048 shares of the medical equipment provider’s stock valued at $5,856,000 after buying an additional 1,609 shares in the last quarter. Prudent Man Advisors LLC acquired a new position in Integer during the third quarter worth $209,000. Intech Investment Management LLC acquired a new position in Integer during the third quarter worth $1,012,000. Finally, Charles Schwab Investment Management Inc. raised its position in Integer by 1.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 404,029 shares of the medical equipment provider’s stock worth $52,524,000 after acquiring an additional 4,946 shares in the last quarter. Institutional investors own 99.29% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ITGR shares. Oppenheimer lowered shares of Integer from an “outperform” rating to a “market perform” rating in a research note on Friday, February 21st. Truist Financial upped their price objective on Integer from $147.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Citigroup lifted their target price on Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, December 11th. KeyCorp increased their price target on Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Finally, Benchmark lifted their price objective on shares of Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Integer presently has a consensus rating of “Moderate Buy” and an average target price of $149.00.

Integer Trading Down 0.4 %

ITGR stock opened at $118.87 on Wednesday. Integer Holdings Co. has a 52 week low of $107.11 and a 52 week high of $146.36. The company has a market capitalization of $4.00 billion, a PE ratio of 35.38, a price-to-earnings-growth ratio of 1.72 and a beta of 1.24. The company’s 50-day simple moving average is $133.56 and its 200 day simple moving average is $132.61. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.09 and a current ratio of 2.95.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing the consensus estimate of $1.46 by ($0.03). The business had revenue of $449.50 million for the quarter, compared to the consensus estimate of $446.28 million. Integer had a return on equity of 11.65% and a net margin of 6.92%. As a group, sell-side analysts anticipate that Integer Holdings Co. will post 6.01 earnings per share for the current year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.